Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Covid-19 | D000086382 | — | — | — | 2 | 1 | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | — | — | 1 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | 1 | — | — | — | 1 |
Sars-cov-2 | D000086402 | — | — | — | 1 | — | — | — | 1 |
Drug common name | Upamostat |
INN | upamostat |
Description | Upamostat (WX-671, Mesupron) is a drug which acts as an inhibitor of the serine protease enzyme urokinase. It is under development as a potential treatment agent for pancreatic cancer, acting to inhibit tumour metastasis.
|
Classification | Small molecule |
Drug class | enzyme inhibitors: proteolytic enzyme inhibitors |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CCOC(=O)N1CCN(C(=O)[C@H](Cc2cccc(/C(N)=N\O)c2)NS(=O)(=O)c2c(C(C)C)cc(C(C)C)cc2C(C)C)CC1 |
PDB | — |
CAS-ID | 1191101-18-4 |
RxCUI | — |
ChEMBL ID | CHEMBL4206119 |
ChEBI ID | — |
PubChem CID | 9852201 |
DrugBank | DB13052 |
UNII ID | S5M7KW6U17 (ChemIDplus, GSRS) |